Congress quietly expands drug compounding to bypass shortages—with minimal FDA oversight
H.R. 5316 — Drug Shortage Compounding Patient Access Act of 2025 · Filed by Diana Harshbarger (R-TN) · 3 cosponsors · Introduced Sep 11, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill expands pharmacy compounding rules to allow pharmacists and physicians to make copies of drugs in short supply without a specific patient prescription, provided they follow strict tracking and reporting requirements. It also strengthens FDA reporting rules for drug shortages and surges in demand, requiring manufacturers to notify the agency sooner and more completely.
Why we flagged it
The bill's core function is to create a regulatory carve-out for emergency compounding during drug shortages while simultaneously tightening FDA reporting and tracking requirements. It is a public-health measure, not a corporate giveaway or vanity provision.
What the text implies
- Compounding pharmacies and outsourcing facilities gain new revenue streams from emergency shortage compounding, potentially creating financial incentives to tolerate or underreport shortages.
- The 60-day lookback window for shortage status may allow compounding to continue even after a shortage officially ends, creating a lag in market reversion.
The full analysis lists 4 implications of this text.
Who stands to gain
pharmacy compounding services; outsourcing facilities (503B); specialty pharmaceutical manufacturers